



Lynparza in Egypt

The EDA named-patient coordination pathway — indicative 2026

ONCOLOGY · BRCA/HRD PARP INHIBITOR

The clinical situation

Lynparza (olaparib) is an FDA-approved oral PARP-1/2 inhibitor dosed 300 mg twice daily for BRCA-mutated or HRD-positive advanced ovarian, breast, pancreatic, and prostate cancers as maintenance or treatment per indication. Manufactured by AstraZeneca (with Merck). Requires documented BRCA1/2 or HRD testing and a stage-specific indication match.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist confirms BRCA/HRD status and documents a written clinical rationale and prior line history.
- 2 Treatment facility confirmed.** An Egyptian oncology centre (Cairo or Alexandria tertiary facility) accepts the case and sets the treatment plan.
- 3 EDA named-patient application.** Clinical rationale, patient reference, product details, and chain-of-custody plan are filed with the Egyptian Drug Authority.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner, booked to your initiation date.
- 5 Arrival & administration.** The facility receives the product and initiates under your oncologist's care; ongoing cycles dispensed per the protocol.

Indicative economics

Reference US cash-pay range: USD 14,000–17,000 per 30-day supply. EDA documentation, logistics, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete EDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and EDA review. **Logistics.** Temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Lynparza × Egypt first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/lynparza-egypt.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team